Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Talk to the deal team
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.Learn more
Change Financial (ASX:CCA) has raised US$4 million
Change Financial has completed a capital raise to help accelerate product enhancement, repay its debt, provide working capital and cover the costs of the offer.Learn more
Agar Scientific has been acquired by Calibre Scientific
Agar Scientific Ltd. (Agar) has been sold to Molecular Dimensions Limited, a subsidiary of Calibre Scientific, Inc., a US-based life sciences company, owned by international private investment firm StoneCalibre.Learn more